title: Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
abstract: Leishmania donovani is an intracellular protozoan parasite that causes leishmaniasis, which can range from a self-healing cutaneous disease to a fatal visceral disease depending on the infecting species. Miltefosine is currently the latest and only oral antileishmanial that came out of drug discovery pipelines in the past few decades, but recent reports indicate a significant decline in its efficacy against visceral leishmaniasis (also known as kala-azar) in the Indian subcontinent. This relapse rate of up to 20% within 12 months after treatment was shown not to be related to reinfection, drug quality, drug exposure, or drug-resistant parasites. We therefore aimed to assess other phenotypes of the parasite that may affect treatment outcome and found a significant association between the number of metacyclic parasites, parasite infectivity, and patient treatment outcome in the Indian subcontinent. Together with previous studies on resistance of L. donovani against pentavalent antimonials, these data suggest that the infectivity of the parasite, or related phenotypes, might be a more determinant factor for treatment failure in visceral leishmaniasis than drug susceptibility, warranting a reassessment of our current view on treatment failure and drug resistance in leishmaniasis and beyond.
  
  
  OBJECTIVE
  The high miltefosine relapse rate poses a major challenge for the current Kala-Azar Elimination Program in the Indian subcontinent and other leishmaniasis control programs worldwide. This relapse rate could not be related to reinfection, drug-resistant parasites, or reduced treatment quality. Here we report that an increased infectivity of the parasite is associated with miltefosine relapse of visceral leishmaniasis (VL) patients. These results supplement those obtained with antimonial-resistant L. donovani where an increased infectivity was also observed. This challenges the current view of Leishmania drug susceptibility being the biggest parasitic factor that contributes to treatment failure in leishmaniasis. These selected more infectious parasites may pose an additional burden to leishmaniasis control programs, highlighting the importance of multifaceted control measures to achieve leishmaniasis elimination in the Indian subcontinent and other regions where leishmaniasis is endemic.
authors.affiliation: Molecular Parasitology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
authors.forename: Keshav
authors.initials: K
authors.lastname: Rai
authors.forename: Bart
authors.initials: B
authors.lastname: Cuypers
authors.forename: Narayan Raj
authors.initials: NR
authors.lastname: Bhattarai
authors.forename: Surendra
authors.initials: S
authors.lastname: Uranw
authors.forename: Maya
authors.initials: M
authors.lastname: Berg
authors.forename: Bart
authors.initials: B
authors.lastname: Ostyn
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Dujardin
authors.forename: Suman
authors.initials: S
authors.lastname: Rijal
authors.forename: Manu
authors.initials: M
authors.lastname: Vanaerschot
mesh_terms: D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006801:Humans; D007893:Leishmania donovani / Q000187:drug effects* / Q000472:pathogenicity* / Q000502:physiology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012008:Recurrence; D014774:Virulence / Q000187:drug effects
chemical_list: D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine